PepGen Inc (PEPG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.11-2.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PEPG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PEPG — debt issuance
Dated 2025-09-26
Entry into a Material Definitive Agreement. On September 24, 2025, PepGen Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as joint book-running managers (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 31,250,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of…
Why it matters: Updates on cash runway show the company's financial health. This affects how investors feel.
Watch forEarnings report shows cash runway extending well into 2027.
Also watch forThe earnings report shows the cash runway is shorter than before.
Why it matters: Results will show how the treatment works at higher doses. This may affect rules.
Supportive ifGood results from the 12.5 mg/kg group support the treatment's safety and effectiveness.
Worry ifNegative results from the 12.5 mg/kg cohort lead to doubts about the treatment's viability.
Why it matters: Updates on this group will show how the company is doing with its trials. This is important for future talks with regulators.
Supportive ifEnrollment in the 12.5 mg/kg cohort is completed and data is on track for 1H 2027.
Worry ifEnrollment in the 12.5 mg/kg cohort is delayed or fails to meet expectations.
Why it matters: Data from this cohort will show if PGN-EDODM1 is effective at this dose. Positive results could support further development.
Supportive ifData from the 10 mg/kg group shows better safety and effectiveness.
Worry ifData from the 10 mg/kg group shows no better safety or effectiveness. It may be worse.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$324 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $871 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,117 loss on $10,000 · 81.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.